• Explore /
  • Poster
  • / Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC).

Randomized phase 2 study to assess the safety and efficacy of CRLX101 in combination with bevacizumab in patients (pts.) with metastatic renal cell carcinoma (RCC) versus standard of care (SOC).

Abstract Poster

Authors

Martin Voss

Martin Henner Voss

Memorial Sloan Kettering Cancer Center, New York, NY

Martin Henner Voss , Andrea Coates , Edward Graeme Garmey , Naomi B. Haas , Thomas Hutson , Stephen Michael Keefe , Robert Motzer , Anthony Piscitelli , Nicholas J. Vogelzang , Robert A. Figlin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT02187302

Citation

J Clin Oncol 33, 2015 (suppl; abstr TPS4579)

DOI

10.1200/jco.2015.33.15_suppl.tps4579

Abstract #

TPS4579

Poster Bd #

248b

Abstract Disclosures

Similar Posters

First Author: Zev A. Wainberg

First Author: Meredith Pelster

First Author: Hideaki Bando

First Author: Zhichao Jiang